spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  HCC 

 HSMN NewsFeed - 5 Dec 2023
ABK Biomedical Announces That its Eye90 Microspheres(R) Device Has Been Granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)
Devices Oncology FDA
 HSMN NewsFeed - 12 Apr 2023
Geneos Therapeutics Secures $5 Million in Series A3 Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 14 Mar 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Jan 2022
Alpha Tau Announces New Research Collaboration to Study the Potential of Alpha DaRT to Enhance Immune Stimulation in the Treatment of Breast Cancer
Devices Oncology
 HSMN NewsFeed - 10 Jan 2022
Alpha Tau Announces Results of First US Clinical Trial of Alpha DaRT(TM) in Malignant Skin & Soft Tissue Cancers, Showing Complete Response in All Ten Treated Tumors at Approximately 12 Weeks and No Product-Related Serious Adverse Events
Devices Oncology
 HSMN NewsFeed - 3 Jan 2022
Alpha Tau Announces Completion of Enrollment of Japanese Pivotal Clinical Trial in Recurrent Head & Neck Cancer
Devices Oncology
 HSMN NewsFeed - 13 Dec 2021
Hyperfine Appoints New Board of Directors
Devices Radiology Personnel
 HSMN NewsFeed - 29 Nov 2021
Hyperfine Receives FDA Clearance for Deep Learning Portable MRI, Defining the Future of Life-Saving Diagnostics
Devices Radiology FDA
 HSMN NewsFeed - 11 Oct 2021
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of SIR-Spheres(R) Y-90 resin microspheres in China
Devices Oncology
 HSMN NewsFeed - 6 Sep 2021
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2021
Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
Devices Oncology
 HSMN NewsFeed - 18 Mar 2021
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Devices Oncology FDA
 HSMN NewsFeed - 13 Nov 2020
Positive Data Presented on Helio Health Liver Test for the Detection of Hepatocellular Carcinoma (HCC) Advances Product Development
Diagnostics Oncology
 HSMN NewsFeed - 5 Oct 2020
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jun 2020
SFA Therapeutics Announces FDA Approval To Begin IND Trial
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Apr 2020
Medivir Receives Positive Opinion on Orphan Medicinal Drug Designation by the European Medicines Agency for MIV-818
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Oct 2019
SFA Therapeutics, Inc. Receives an FDA Orphan Drug Designation (ODD) for SFA001 in the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2019
Laboratory for Advanced Medicine Receives FDA Breakthrough Device Designation for Liquid Biopsy Liver Cancer Detection Test
Diagnostics Oncology FDA
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2019
Recommendations for Personalised HCC Treatment With Y90 TheraSphere(TM) Published by an International Multidisciplinary Group
Devices Interventional Oncology
 HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 1 Apr 2019
Artios Pharma Announces Appointment of Dr. Ian Smith as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Sep 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Aug 2018
Eisai And Merck Announce FDA Approval Of LENVIMA(R) (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Jul 2018
OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 28 May 2018
Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 2 Mar 2018
CARsgen Completed $60 Million Pre-C Financing Framework Agreements
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 19 Jan 2018
Independent Imaging Review Confirmed Positive Data from Primary Analysis of REFLECT Trial Evaluating Lenvatinib Compared to Sorafenib in Unresectable Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2017
SIR-Spheres(R) Y-90 Resin Microspheres Substantially Improves Quality of Survival in Primary Liver Cancer, New Study Against Standard Treatment Shows
Devices Oncology
 HSMN NewsFeed - 21 Apr 2017
Eight Weeks of Treatment with AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Achieved High SVR(12) Rates in Challenging to Treat Genotype 3 Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2017
Upcoming National Healthcare CFO Summit 2017
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2016
First Patient in Malaysia Receives TheraSphere(TM) Radioembolization Therapy
Devices Oncology
 HSMN NewsFeed - 14 Oct 2016
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y(TM) Dosimetry Software in Europe
Devices Oncology Regulatory
 HSMN NewsFeed - 11 Oct 2016
New European Society of Medical Oncology (ESMO) Biliary Cancer Guidelines Indicate Selective Internal Radiation Therapy (SIRT) with Y-90 Microspheres as an Option for Post-Chemotherapy Treatment of Intrahepatic Cholangiocarcinoma (iCCA)
Devices Oncology
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Sep 2016
BioLineRx Announces In-licensing of Novel Treatment for Liver Failure Conditions Under Strategic Collaboration
Biopharmaceuticals Licensing
 HSMN NewsFeed - 26 May 2016
New Study Highlights Potential Cost Savings When Using Yttrium-90 Glass Microspheres for Treatment of Hepatocellular Carcinoma
Devices Oncology
 HSMN NewsFeed - 31 Mar 2016
SIR-Spheres(R) Y-90 Resin Microspheres Are a Well-Tolerated Alternative to Standard Therapies for Inoperable Primary Liver Cancer, New UK NICE Medtech Innovation Briefing Says
Devices Oncology
 HSMN NewsFeed - 25 Jan 2016
CARsgen Therapeutics Completes $30 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Jan 2016
Millennium Healthcare Inc. Announces New Healthcare Product Launch
Devices Urology Product Launch
 HSMN NewsFeed - 8 Dec 2015
Delcath Announces CHEMOSAT Review Accepted for Publication in Cardiovascular and Interventional Radiology
Devices Drug Delivery Interventional Oncology Radiology
 HSMN NewsFeed - 2 Dec 2015
Surefire Medical Closes $15M Series C Financing Led by Tullis Health Investors
Devices Interventional Radiology Oncology Venture Capital
 HSMN NewsFeed - 30 Sep 2015
Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2015
Surefire Medical Launches Advanced Precision Direct-To-Tumor Infusion System At CIRSE
Devices Interventional Oncology Product Launch
 HSMN NewsFeed - 1 Sep 2015
Surefire Medical Receives FDA Clearance for Precision Direct-to-Tumor Embolization Device
Devices Drug Delivery Interventional Oncology FDA
 HSMN NewsFeed - 9 Jun 2015
Healthcare Executive Noel Mijares to Join Millennium Healthcare Inc. as New CEO
Devices Distribution Personnel
 HSMN NewsFeed - 8 May 2015
Provectus Biopharmaceuticals Updates Market on Business Developments
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 23 Feb 2015
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jul 2014
Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox(R) in Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jul 2014
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR(R) (sorafenib) in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jul 2014
Nexavar(R) (sorafenib tablets) now Approved in Canada for the Treatment of Differentiated Thyroid Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jun 2014
Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2014
Surefire Medical's Groundbreaking COSY Clinical Trial Results Presented at ECIO: Is Coiling Prior to Radioembolization Still Necessary in Minimally Invasive Treatment of Liver Cancer?
Devices Interventional Oncology
 HSMN NewsFeed - 11 Mar 2014
Bayer and Onyx Report Phase 3 Study Results of NEXAVAR(R) (sorafenib) as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Feb 2014
Celsion Announces FDA Clearance of the OPTIMA Study - A Pivotal Phase III Trial of ThermoDox in Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 May 2013
Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
Devices Diagnostics Distribution
 HSMN NewsFeed - 23 Apr 2013
Celsion Corporation Provides Business Update
Biopharmaceuticals Devices Drug Delivery Oncology
 HSMN NewsFeed - 3 Jan 2013
Phase 3 DECISION Trial of Nexavar(R) (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2012
Sirtex Medical Limited Launches New Global Website for SIR-Spheres(R) Microspheres - A Form of Selective Internal Radiation Therapy (SIRT) for Liver Tumours
Devices Oncology
 HSMN NewsFeed - 15 Oct 2012
Cheng Ching General Hospital Delivers First TrueBeam STx Radiosurgery Treatments in Taiwan
Devices Oncology
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2012
Nordion Announces Europe-Focused Phase III Clinical Trial for TheraSphere(R) Liver Cancer Treatment
Devices Oncology
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Oct 2011
Onyx Pharmaceuticals and Bayer Healthcare Restructure Global Oncology Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Oct 2011
Ligand Enters Into Global Licensing Agreement With Chiva Pharmaceuticals for Fablyn(R)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jul 2011
Polaris Group Doses First Patient in Pivotal Phase 3 Clinical Trial of Lead Therapeutic Candidate ADI-PEG 20 for the Treatment of Hepatocellular Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Mar 2011
Celsion Receives European Orphan Drug Designation for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Feb 2011
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2010
First U.S. Patient Treated with the Accu2i Percutaneous Microwave Tissue Ablation Device (pMTA)
Devices Oncology
 HSMN NewsFeed - 4 Oct 2010
Celsion Receives Positive FDA Guidance for its New Drug Application for ThermoDox(R) to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Sep 2010
Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2010
Celsion Receives Fast Track Designation for ThermoDox(R) Development Program to Treat Primary Liver Cancer
Biopharmaceuticals Drug Delivery Oncology FDA
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Apr 2010
AngioDynamics Announces First Patient Treatment and Ongoing Enrollment in the Clinical Trial of the Use of IRE Technology in the Treatment of Early Stage Primary Liver Cancer
Devices Oncology
 HSMN NewsFeed - 10 Feb 2010
Data Monitoring Committee Recommends Continuation of Celsion's Phase III ThermoDox(R) Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 23 Nov 2009
Light Sciences Oncology Elects Akbar Seddigh, Chairman of Elekta AB to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 Oct 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Sep 2009
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 May 2009
The Ottawa Hospital and Elekta Forge Long-Term Strategic Partnership Agreement
Devices Oncology
 HSMN NewsFeed - 20 May 2009
Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Mar 2009
Celsion Receives Orphan Drug Designation for ThermoDox to Treat Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Jul 2008
Nexavar Approved for Liver Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2008
FDA Approves EOVIST(R) to Detect and Characterize Focal Liver Lesions
Biopharmaceuticals Radiology FDA
 HSMN NewsFeed - 16 May 2008
Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2008
Sirtex Sponsors Pilot Study Evaluating SIR-Spheres(R) Microspheres for the Treatment of Unresectable Hepatocelluar Carcinoma
Devices Interventional Oncology
 HSMN NewsFeed - 12 Mar 2008
Celsion Commences Global Phase III Study for Primary Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jan 2008
BioSphere Medical Receives Market Clearance to Sell Embosphere(R) Microspheres in the People's Republic of China
Devices Regulatory
 HSMN NewsFeed - 19 Nov 2007
Nexavar First FDA-Approved Drug Therapy for Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2007
Nexavar Becomes First and Only Approved Treatment of Hepatocellular Carcinoma in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Oct 2007
Metabasis Announces European Commission Grants Orphan Medicinal Product Designation to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2007
US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2007
Nexavar Receives Positive Opinion from European Committee for Medicinal Products for Human Use for Treatment of Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Sep 2007
NCCN Updates Hepatobiliary Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
Metabasis Announces Orphan Drug Designation Granted to MB07133, Its Product Candidate for the Treatment of Primary Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Aug 2007
Nexavar Granted FDA Priority Review for Treatment of Liver Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2007
Bayer and Onyx Submit Supplemental New Drug Application for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
Bayer and Onyx Submit New European Marketing Authorization Application to EMEA for Nexavar to Treat Liver Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
Metabasis Therapeutics Presents Results of a Clinical Study for Its Novel Liver-Targeted Product Candidate for the Treatment of HCC at American Association for Cancer Research
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2007
Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jan 2007
Light Sciences Oncology Receives Special Protocol Assessment for Pivotal Phase III Trial of Litx(TM) Therapy in Metastatic Colorectal Cancer
Devices Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Dec 2006
SciClone Submits Regulatory Application for DC Bead in China
Biopharmaceuticals Drug Delivery Oncology Regulatory
 HSMN NewsFeed - 13 Dec 2006
Lapatinib (Tykerb(R)) to be Evaluated in Early Stage Disease in Adjuvant Breast Cancer Settings Internationally
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Oct 2006
BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jul 2006
BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory Departments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2006
BioAlliance Pharma Strengthens Operational Management Ahead of Loramyc(R) Launch
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 May 2006
pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of Multicenter Clinical Trial
Biopharmacetuicals Oncology Drug Delivery
 HSMN NewsFeed - 16 May 2006
BioAlliance Pharma Boosts Business Development Operations in Europe and US
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 48

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 48 additional stories matching:
HCC
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.